Mikkel Lundbech1,2, Andreas Engel Krag1,3, Lene Hjerrild Iversen2,4, Anne-Mette Hvas5,6. 1. Department of Clinical Biochemistry, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark. 2. Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. 3. Department of Plastic and Breast Surgery, Aarhus University Hospital, Aarhus, Denmark. 4. Department of Surgery, Aarhus University Hospital, Aarhus, Denmark. 5. Department of Clinical Biochemistry, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark. am.hvas@dadlnet.dk. 6. Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. am.hvas@dadlnet.dk.
Abstract
PURPOSE: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has improved survival for selected patients with peritoneal metastases from colorectal cancer. Previous studies report conflicting rates of postoperative bleeding and venous thromboembolism (VTE) after CRS + HIPEC. The aim of the present study was to systematically review the literature and to estimate the overall 30-day incidence of postoperative bleeding and the overall 90-day incidence of VTE after CRS + HIPEC. METHODS: Studies were identified in PubMed, Embase, and Web of Science on 29 April 2021. Data were extracted for a qualitative synthesis and to estimate an overall mean incidence in the meta-analysis. RESULTS: Fourteen studies with a total of 3268 patients were included in the systematic review. Postoperative bleeding incidence rates within 30 days ranged from 1.7 to 8.3% with an overall 30-day postoperative bleeding incidence with [95% CI] at 4.2 [2.6;6.2]%. VTE incidence rates within 90 days ranged from 0.2 to 13.6% with an overall 90-day VTE incidence with [95% CI] at 2.7 [1;5.2]% after CRS + HIPEC. CONCLUSION: This systematic review and meta-analysis indicate a low risk for postoperative bleeding within 30 days and VTE within 90 days after CRS + HIPEC for peritoneal metastases from colorectal cancer.
PURPOSE: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has improved survival for selected patients with peritoneal metastases from colorectal cancer. Previous studies report conflicting rates of postoperative bleeding and venous thromboembolism (VTE) after CRS + HIPEC. The aim of the present study was to systematically review the literature and to estimate the overall 30-day incidence of postoperative bleeding and the overall 90-day incidence of VTE after CRS + HIPEC. METHODS: Studies were identified in PubMed, Embase, and Web of Science on 29 April 2021. Data were extracted for a qualitative synthesis and to estimate an overall mean incidence in the meta-analysis. RESULTS: Fourteen studies with a total of 3268 patients were included in the systematic review. Postoperative bleeding incidence rates within 30 days ranged from 1.7 to 8.3% with an overall 30-day postoperative bleeding incidence with [95% CI] at 4.2 [2.6;6.2]%. VTE incidence rates within 90 days ranged from 0.2 to 13.6% with an overall 90-day VTE incidence with [95% CI] at 2.7 [1;5.2]% after CRS + HIPEC. CONCLUSION: This systematic review and meta-analysis indicate a low risk for postoperative bleeding within 30 days and VTE within 90 days after CRS + HIPEC for peritoneal metastases from colorectal cancer.
Authors: Vic J Verwaal; Serge van Ruth; Eeclo de Bree; Gooike W van Sloothen; Harm van Tinteren; Henk Boot; Frans A N Zoetmulder Journal: J Clin Oncol Date: 2003-10-15 Impact factor: 44.544
Authors: Paul H Sugarbaker; Robert Alderman; Gary Edwards; Christina Ellen Marquardt; Vadim Gushchin; Jesus Esquivel; David Chang Journal: Ann Surg Oncol Date: 2006-03-10 Impact factor: 5.344
Authors: Anke M J Kuijpers; Boj Mirck; Arend G J Aalbers; Simon W Nienhuijs; Ignace H J T de Hingh; Martinus J Wiezer; Bert van Ramshorst; Robert J van Ginkel; Klaas Havenga; Andreas J Bremers; Johannes H W de Wilt; Elisabeth A Te Velde; Vic J Verwaal Journal: Ann Surg Oncol Date: 2013-07-30 Impact factor: 5.344
Authors: R Mirnezami; A M Mehta; K Chandrakumaran; T Cecil; B J Moran; N Carr; V J Verwaal; F Mohamed; A H Mirnezami Journal: Br J Cancer Date: 2014-09-16 Impact factor: 7.640